Roche and IBM Collaborate to Develop DNA Sequencing Technology
Roche (Branford, CT) and IBM (Yorktown Heights, NY) have announced a partnership to develop a nanopore-based sequencer that will directly read and decode human DNA quickly and efficiently. Developed by IBM Research, the novel technology offers true single molecule sequencing by decoding molecules of DNA as they are threaded through a nanometer-sized pore in a silicon chip.
“By merging computational biology, biotechnology, and nanotechnology skills, we are moving closer to producing a system that can quickly and accurately translate DNA into medically-relevant genetic information,” said Ajay Royyuru, Senior Manager of the Computational Biology Department at IBM Research. “The challenge of all nanopore-based sequencing technologies is to slow and control the motion of the DNA through the nanopore. We are developing the technology to achieve this so that the reader can accurately decode the DNA sequence.”
As part of the agreement, Roche will fund continued development of the technology at IBM and provide additional resources and expertise through collaboration with Roche’s sequencing subsidiary, 454 Life Sciences. Roche will develop and market all products based on the technology.
Roche’s investment in future genomic technologies builds upon the strength of its currently available 454 Sequencing Systems, which generate hundreds of thousands of long, high quality sequencing reads in hours. The technology is available for large-scale genomic analysis with the GS FLX System and for benchtop sequencing with the GS Junior System. Shown to provide significant medical value in targeted resequencing applications for virology and oncology research, 454 Sequencing Systems are poised to be first next-generation sequencing technology to move from the laboratory to the clinic.
For more information on 454 Sequencing Systems, visit www.454.com.